Table 2. Distribution of initial treatments in the study population stratified by age and performance.
| Treatment choices | Age group* |
ECOG PS group+ |
|||
|---|---|---|---|---|---|
| 65–70 (n = 35) | 71–80 (n = 68) | ≥81 (n = 30) | 0–1 (n = 98) | 2–4 (n = 35) | |
| No treatment or steroid monotherapy (n, %) | 2 (5.7) | 12 (17.6) | 9 (30) | 8 (8.2) | 15 (42.9) |
| R-CHOP (n, %) | 27 (77.1) | 31 (45.6) | 5 (16.7) | 56 (57.1) | 7 (20) |
| R-COP (n, %) | 5 (14.3) | 24 (35.3) | 12 (40) | 32 (32.7) | 9 (25.7) |
| Other regimens (n, %) | 1 (2.9) | 1 (1.5) | 4 (13.3) | 2 (2.0) | 4 (11.4) |
*P-value < 0.001.
+P-value < 0.001.
Other regimens included the following combinations: rituximab, vincristine, and prednisolone; rituximab and prednisolone. ECOG PS, Eastern Cooperative Oncology Group Performance Status; R, rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; COP, cyclophosphamide, vincristine, and prednisolone.